Equities

Purple Biotech Ltd

Purple Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)18.10
  • Today's Change-0.20 / -1.09%
  • Shares traded109.41k
  • 1 Year change-73.34%
  • Beta-0.3505
Data delayed at least 20 minutes, as of May 16 2024 15:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-73.43m
  • Incorporated1968
  • Employees20.00
  • Location
    Purple Biotech Ltd4 Oppenheimer St., Science ParkREHOVOT 7670104IsraelISR
  • Phone+972 39333121
  • Fax+972 35097196
  • Websitehttps://purple-biotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Millennium Food-Tech LP464.00k-25.91m19.26m2.00--0.1713--41.51-0.9204-0.92040.0183.440.0038--3.40232,000.00-21.38---21.52-------5,584.27-----0.170.00--224.48---84.01------
Kadimastem Ltd0.00-12.01m20.50m32.00---------1.22-1.220.00-1.040.00-------115.17-155.33-1,153.60-1,831.12-----------9.443.22------47.14---50.73--
Nextage Therapeutics Ltd876.00k-4.07m22.69m--------25.90-0.1396-0.13960.03-0.09580.672--6.82---322.44-188.94---423.7625.6833.33-479.79-2,486.19---18.46------17.9927.21------
Tikun Olam Cannbit Pharmaceuticals Ltd44.23m-88.89m31.01m51.00--0.7226--0.7012-1.43-1.430.70180.50510.3792.8719.85867,215.70-80.56-30.17-99.81-35.04-0.4273---212.57-146.420.5033-30.020.3778---10.28---84.28---8.71--
Can Fite Biopharma Ltd2.74m-28.20m39.18m5.00--1.54--14.28-0.0224-0.02240.00220.0170.0771----548,883.80-79.22-102.29-103.51-131.07-----1,027.46-1,105.36----0.00---8.27-27.9224.96---42.92--
Wilk Technologies Ltd0.00-10.93m42.46m4.00--6.14-----0.1807-0.18070.000.10060.00-------80.10-266.55-96.15-298.65-------97,340.88---39.620.4049------36.02------
Grace Breeding Ltd463.00k-8.50m44.22m----27.89--95.51-2.36-2.250.12960.39980.08482.730.9636---164.09---206.24--80.56---1,935.21--1.45-94.740.5103--121.53--23.10------
Purple Biotech Ltd0.00-73.43m49.08m20.00--0.3579-----0.313-0.3130.000.50060.00----0.00-40.39-37.24-47.34-41.28-------9,415.70----0.0101------8.25---28.45--
Cannassure Therapeutics Ltd11.00m-1.18m50.82m------182.804.62-1.43-2.1613.28-3.660.53291.374.47---5.74-45.39-18.34-92.4129.17---10.77-83.490.04740.9011-----67.44--78.37---72.23--
X T L Biopharmaceuticals Ltd1.68m-83.07m54.85m33.00--0.6605--32.71-0.3772-0.37720.00760.15240.0192--0.701250,816.36-94.96-53.17-111.98-59.10---2.33-4,953.75-1,084.42----0.00---85.80---7.97---53.12--
Matricelf Ltd0.00-13.83m66.42m----2.48-----0.8777-0.87770.001.670.00-------39.69---42.80--------------0.0527-------10.77------
DNA Group TR Ltd306.00k-1.18m114.05m14.00--1.44--372.71-0.0088-0.00880.00250.64290.0038--1.3721,857.14-1.45-23.54-1.46-26.27-----384.64-7,406.24----0.00---45.36--95.00------
GFC Green Fields Capital Ltd0.0015.70m123.57m2.007.900.78077.87--1.561.560.0015.770.00------3.261.9910.383.58------------0.00------844.9045.32----
Data as of May 16 2024. Currency figures normalised to Purple Biotech Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

0.48%Per cent of shares held by top holders
HolderShares% Held
Meitav Mutual Funds Ltd.as of 29 Feb 2024578.16k0.22%
KSM Mutual Funds Ltd.as of 29 Feb 2024367.13k0.14%
Migdal Mutual Funds Ltd.as of 29 Feb 2024226.88k0.09%
Psagot Mutual Funds Ltd.as of 29 Feb 202443.50k0.02%
Harel Mutual Funds Ltd.as of 29 Feb 202414.93k0.01%
Lamashkia Mutual Funds Management Co. (1982) Ltd.as of 30 Jun 20210.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.